Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

~7 mi. (Geleen, Netherlands, +120 more cities)

Zuyderland Medisch Centrum Sittard-Geleen

FGFR3 A391E, +9 more biomarkers

Urothelial Carcinoma

infigratinib

targeted therapy

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~9 mi. (Sittard, Netherlands, +93 more cities)

Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

~9 mi. (Sittard, Netherlands, +54 more cities)

Orbis Medical Center

Colorectal Carcinoma

bevacizumab, +6 more drugs

chemotherapy, +1 more type

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~13 mi. (Maastricht, Netherlands, +192 more cities)

Maastricht UMC+

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~13 mi. (Maastricht, Netherlands, +89 more cities)

Maastricht UMC+-Medical Oncology ( Site 1353)

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~13 mi. (Maastricht, Netherlands, +226 more cities)

Maastricht University Medical Centre ( Site 0467)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

~13 mi. (Maastricht, Netherlands, +140 more cities)

Maastricht University Medical Centre ( Site 0440)

Hepatocellular Carcinoma

lenvatinib, +2 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

~13 mi. (Maastricht, Netherlands, +130 more cities)

Maastricht University Medical Centre ( Site 0453)

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~13 mi. (Maastricht, Netherlands, +206 more cities)

Maastricht Universitair Medisch Centrum

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

~13 mi. (Maastricht, Netherlands, +209 more cities)

Maastricht University Medical Center

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

~13 mi. (Maastricht, Netherlands, +8 more cities)

Maastricht UMC+-Medical Oncology ( Site 1501)

Biliary Tract Carcinoma, +3 more conditions

belzutifan, +2 more drugs

immunotherapy, +1 more type

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

~13 mi. (Maastricht, Netherlands, +26 more cities)

Regeneron Research Site

CDKN2A Overexpression, +1 more biomarker

Cervical Squamous Cell Carcinoma

cemiplimab, +1 more drug

immunotherapy